Latest SUPERSTRING CAPITAL MANAGEMENT LP Stock Portfolio

SUPERSTRING CAPITAL MANAGEMENT LP Performance:

2025 Q4: 28.85%YTD: 60.47%2024: -27.98%

Performance for 2025 Q4 is 28.85%, and YTD is 60.47%, and 2024 is -27.98%.

About SUPERSTRING CAPITAL MANAGEMENT LP and 13F Hedge Fund Stock Holdings

On 2026-02-17, the fund reported it's updated stock portfolio. In the 13F Holdings report, SUPERSTRING CAPITAL MANAGEMENT LP reported an equity portfolio of $186.8 Millions as of 31 Dec, 2025.

The top stock holdings of SUPERSTRING CAPITAL MANAGEMENT LP are CDTX, TERN, URGN. The fund has invested 10.1% of it's portfolio in CIDARA THERAPEUTICS INC and 9.6% of portfolio in TERNS PHARMACEUTICALS INC .

The fund managers got completely rid off 89BIO INC (ETNB), JAZZ PHARMACEUTICALS PLC (JAZZ) and BRIDGEBIO PHARMA INC (BBIO) stocks. They significantly reduced their stock positions in TERNS PHARMACEUTICALS INC (TERN), TRAVERE THERAPEUTICS INC (TVTX) and SAVARA INC (SVRA). SUPERSTRING CAPITAL MANAGEMENT LP opened new stock positions in DYNAVAX TECHNOLOGIES CORP (DVAX), SIONNA THERAPEUTICS INC and AXSOME THERAPEUTICS INC (AXSM). The fund showed a lot of confidence in some stocks as they added substantially to UROGEN PHARMA LTD (URGN), ORIC PHARMACEUTICALS INC (ORIC) and CABALETTA BIO INC (CABA).

SUPERSTRING CAPITAL MANAGEMENT LP Annual Return Estimates Vs S&P 500

Our best estimate is that SUPERSTRING CAPITAL MANAGEMENT LP made a return of 28.85% in the last quarter. In trailing 12 months, it's portfolio return was 60.47%.

Performance
S&P 500

New Buys

Ticker	$ Bought
dynavax technologies corp	8,083,600
sionna therapeutics inc	7,429,600
axsome therapeutics inc	6,836,760
mind medicine mindmed inc	5,693,460
taysha gene therapies inc	5,394,220
ocular therapeutix inc	5,075,490
amicus therapeutics inc	5,025,240
united therapeutics corp del	4,605,000

New stocks bought by SUPERSTRING CAPITAL MANAGEMENT LP

Additions

Ticker	% Inc.
urogen pharma ltd	717
oric pharmaceuticals inc	185
cabaletta bio inc	45.91
cidara therapeutics inc	24.3
cogent biosciences inc	1.34

Additions to existing portfolio by SUPERSTRING CAPITAL MANAGEMENT LP

Reductions

Ticker	% Reduced
terns pharmaceuticals inc	-43.8
travere therapeutics inc	-29.1
savara inc	-23.97
avalo therapeutics inc	-18.49
immunovant inc	-15.43
zenas biopharma inc	-13.77
bright minds biosciences inc	-12.37
zai lab ltd	-1.88

SUPERSTRING CAPITAL MANAGEMENT LP reduced stake in above stock

Sold off

Ticker	$ Sold
89bio inc	-5,654,380
summit therapeutics inc	-4,075,250
bicara therapeutics inc	-2,777,490
vir biotechnology inc	-858,282
i mab	-528,769
tectonic therapeutic inc	-1,871,600
keros therapeutics inc	-1,504,210
bridgebio pharma inc	-4,604,900

SUPERSTRING CAPITAL MANAGEMENT LP got rid off the above stocks

Sector Distribution

SUPERSTRING CAPITAL MANAGEMENT LP has about 87.1% of it's holdings in Healthcare sector.

Sector	%
Healthcare	87.1
Others	12.9

Market Cap. Distribution

SUPERSTRING CAPITAL MANAGEMENT LP has about 6.7% of it's portfolio invested in the large-cap and mega-cap stocks.

Category	%
MID-CAP	38.4
SMALL-CAP	33.6
UNALLOCATED	12.9
LARGE-CAP	6.7
MICRO-CAP	6.6
NANO-CAP	1.8

Stocks belong to which Index?

About 57.2% of the stocks held by SUPERSTRING CAPITAL MANAGEMENT LP either belong to S&P 500 or RUSSELL 2000 index.

Index	%
RUSSELL 2000	57.2
Others	42.8

Top 5 Winners (%)		%
TERN	terns pharmaceuticals inc	342.0 %
COGT	cogent biosciences inc	145.0 %
CDTX	cidara therapeutics inc	104.5 %
IPSC	century therapeutics inc	99.8 %
SVRA	savara inc	60.6 %

Top 5 Winners ($)		$
TERN	terns pharmaceuticals inc	20.3 M
CDTX	cidara therapeutics inc	9.6 M
COGT	cogent biosciences inc	7.7 M
IMVT	immunovant inc	2.9 M
SVRA	savara inc	2.8 M

Top 5 Losers (%)		%
ZLAB	zai lab ltd	-47.5 %
BMEA	biomea fusion inc	-38.6 %
ORIC	oric pharmaceuticals inc	-24.0 %
CABA	cabaletta bio inc	-5.5 %

Top 5 Losers ($)		$
ZLAB	zai lab ltd	-3.2 M
ORIC	oric pharmaceuticals inc	-0.7 M
CABA	cabaletta bio inc	-0.3 M
BMEA	biomea fusion inc	-0.2 M

SUPERSTRING CAPITAL MANAGEMENT LP Holdings Map

This heatmap illustrates the top 50 positions within the fund's portfolio.

Current Stock Holdings of SUPERSTRING CAPITAL MANAGEMENT LP

SUPERSTRING CAPITAL MANAGEMENT LP has 45 stocks in it's portfolio. About 57.8% of the portfolio is in top 10 stocks. ZLAB proved to be the most loss making stock for the portfolio. TERN was the most profitable stock for SUPERSTRING CAPITAL MANAGEMENT LP last quarter.

Last Reported on: 17 Feb, 2026

Ticker	Namesorted ascending	% Portfolio	Shares Held	$ Value	Type	% Change
ASMB	assembly biosciences inc	1.19	65,273	2,219,940	new

AVTX	avalo therapeutics inc	1.49	153,313	2,784,160	reduced	-18.49

AXSM	axsome therapeutics inc	3.66	37,433	6,836,760	new

BBIO	bridgebio pharma inc	0.00	0.00	0.00	sold off	-100

BLTE	belite bio inc	2.12	24,703	3,951,490	new

BMEA	biomea fusion inc	0.17	250,000	310,000	unchanged	0.00

CABA	cabaletta bio inc	2.64	2,253,550	4,935,280	added	45.91

CAPR	capricor therapeutics inc	1.49	96,334	2,780,200	new

CDTX	cidara therapeutics inc	10.06	85,098	18,797,300	added	24.3

CLDX	celldex therapeutics inc new	1.28	88,308	2,398,440	new

COGT	cogent biosciences inc	6.96	366,238	13,008,800	added	1.34

CRBP	corbus pharmaceuticals hldgs	0.00	0.00	0.00	sold off	-100

DRUG	bright minds biosciences inc	1.98	47,278	3,689,580	reduced	-12.37

DVAX	dynavax technologies corp	4.33	525,592	8,083,600	new

ENTX	entera bio ltd	0.02	17,142	33,255	new

ETNB	89bio inc	0.00	0.00	0.00	sold off	-100

FOLD	amicus therapeutics inc	2.69	352,896	5,025,240	new

FULC	fulcrum therapeutics inc	0.44	72,060	814,999	new

GMAB	genmab a/s	0.48	29,162	898,190	new

IMAB	i mab	0.00	0.00	0.00	sold off	-100